Human origin Hyaluronidase


TERGASE® inj.

TERGASE inj.

Recombinant human hyaluronidase 1500 IU/mL
A high-purity human hyaluronidase formulation
based on recombinant DNA technology
(HYBROZYME™ Technology)



Recombinant Human Hyaluronidase VS Animal-derived



Animal-derived hyaluronidase

- Contains numerous foreign proteins other than target proteins
- Animal-derived genetic toxicity risk
- Human-animal common virus risk



Human Origin Hyaluronidase

- Extremely high purity > 99%
- Primary removal of foreign proteins
- No risk of animal derived diseases or viruses

Tergaze Inj. is a recombinant human hyaluronidase formulation developed based on Alteogen's proprietary recombinant technology, HYBROZYME™ Technology.

Active Ingredient	Recombinant human hyaluronidase 1500 IU/mL **(In accordance with Ph. Eur. hyaluronidase assay)**
Mechanism of Action and Effects	• Facilitates the absorption and dispersion of drugs and local anesthetics during subcutaneous injection, intramuscular injection, and subcutaneous infusion. • Promotes the resorption of excess fluids and blood accumulated in tissues.
Product Features	• **High-Purity Human-Derived Hyaluronidase:** Enhanced safety is expected due to the reduction of impurities and foreign proteins. • **Superior Safety:** Avoids the risks of viral infection and genotoxicity commonly associated with animal-derived formulations. • **Recombinant DNA Technology:** Manufacturing based on recombinant technology ensures uncompromised product consistency and quality stability. • **Safety Evaluation:** Efficacy and safety evaluations have been successfully completed in large-scale global clinical trials, including in South Korea.
Clinical Applications	• **Plastic Surgery:** Breakdown of hyaluronic acid preparations (e.g., fillers) and management of associated side effects. When co-administered during injection therapies aimed at double chin improvement, this formulation promotes the diffusion of the drug within the tissues, contributing to a more uniform local drug distribution. It is also expected to alleviate swelling and pain associated with lifting procedures. • **Internal Medicine / Oncology:** Enhancement of drug delivery efficiency and tissue diffusion. • **Emergency Medicine / Ophthalmology:** Emergency management of conditions such as edema and hematomas.
HYBROZYME™ Technology	A proprietary subcutaneous (SC) formulation platform technology developed by the South Korean biotech company Alteogen. It plays a pivotal role in converting oncology and protein drugs—previously limited to intravenous (IV) administration—into SC formulations that enable convenient self-administration at home. This innovative technology has been successfully out-licensed to multiple leading global pharmaceutical companies. • **MSD:** Signed an exclusive agreement for the subcutaneous formulation of Keytruda, the world's top-selling immunotherapy. • **Daiichi Sankyo:** Entered into a technology partnership agreement to develop a subcutaneous formulation of Enhertu, a next-generation oncology drug. • **Global Collaborations:** Collaborating with more than six global pharmaceutical companies, including Sandoz and AstraZeneca.